Why the study?
Although drug-eluting stents are effective, stent thrombosis remains a major concern in patients with acute myocardial infarction undergoing implantation.
Does a bioabsorbable polymer everolimus-eluting stent improve late stent malapposition and strut coverage compared to a durable polymer zotarolimus-eluting stent in patients with acute myocardial infarction?
Does a bioabsorbable polymer everolimus-eluting stent improve late stent malapposition and strut coverage compared to a durable polymer zotarolimus-eluting stent in patients with acute myocardial infarction?
Contemporary second-generation drug-eluting stents show very low rates of late stent malapposition and uncovered struts at 12 months in AMI patients, regardless of whether a bioabsorbable or durable polymer is used.
No takes yet. Share an insight, caveat, or question.
OCT data on stent healing in AMI are hypothesis-generating; leaves open optimal BP-EES versus DP-ZES selection pending randomized trials.
Lee et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: